H.C. Wainwright Assumes Fate Therapeutics Inc to Buy

Brokerage firm H.C. Wainwright Assumes its rating on Fate Therapeutics Inc(NASDAQ:FATE). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Jul 28, 2016.

Fate Therapeutics Inc (FATE) made into the market gainers list on Thursdays trading session with the shares advancing 0.97% or 0.02 points. Due to strong positive momentum, the stock ended at $2.08, which is also near the day’s high of $2.09. The stock began the session at $2.08 and the volume stood at 1,37,384 shares. The 52-week high of the shares is $8.05 and the 52 week low is $1.46. The company has a current market capitalization of $60 M and it has 2,88,64,054 shares in outstanding.

Fate Therapeutics Inc(FATE) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.32M. Analysts had an estimated revenue of $800.00K. Earnings per share were $-0.29. Analysts had estimated an EPS of $-0.25.

Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *